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Introduction
Although  there are  many  possible  explanations  for
the  increase  in  asthma,  they  can  be  simplified  to
three. The first  was proposed as early  as 1980  and
was based on epidemiology from  a  small  group  of
countries in each of which the increase was related
to  dust  mite  sensitivity.1–3 This  hypothesis  focused
on  the  increase  in  exposure  that  had  occurred
secondary to changes in housing and lifestyle. Over
the next 10 years, it became obvious that increases
had occurred in many countries and regions where
dust mites were not the  dominant indoor allergen.
In  Sweden  and  Finland,  the  increase  was  clearlypresent  in  areas where the primary  allergens  were
derived  from  domestic  animals.  Similarly,  in  the
southwest or mountain states of the USA, the rele-
vant allergens are cat, dog and alternaria.4,5 Finally, it
became  clear  that  cockroaches  were  the  most
important  allergen  related  to  asthma  in  the  major
cities  of  the  USA.6,7 Despite  the  involvement  of
different  allergens,  the  time course of  the increase
appeared  similar  in  many  different  countries  (i.e.
progressive  over  the  period  from  about  1965
through  1995). Without  evidence that exposure  to
these other allergens had increased, or a convincing
explanation  for  an  increase  in  cat  or  cockroach
allergens,  it  became  very  unlikely  that  increasing
exposure  could  explain  all  of  the  epidemic.  How-
ever,  exposure  to  indoor  allergens  may  well  have
increased  because  of  the  increased  time  spent
indoors.
The second group of hypotheses proposed that the
increase  could  be  explained  by  an  alteration  of
immune  responsiveness.8 These proposals focus  on
the many changes in lifestyle that could have shifted
the  balance  between T  helper  cell  (Th)1  and Th2
responses.9,10 The hypothesis is that changes in diet,
immunization,  antibiotic  use  and/or  a  decrease  in
infectious diseases could have led to an increase in
allergic disease. Both of these hypotheses imply that
there has been an increase in allergy in general, in
parallel with the increase in asthma. The actual data
on increases in other allergic diseases are confusing.
In  England,  several  epidemiological  studies  have
suggested  that  hayfever  has  increased  as  much  as
asthma.11 In  the  USA,  it  appears  that  hayfever
increased progressively from 1920 onwards and was
already affecting 16% of the population by 1960 (i.e.
before the major increase in asthma started). Similarly,
comparisons  of  Hong  Kong  with  Mainland  China
suggest that the increase in asthma in ‘westernized’
Hong Kong has not been matched by an increase in
sensitization. If the increase in asthma represents a
selective increase in lung disease or lung symptoms
among the allergic  population, then there are very
different possible explanations.
Immunity to common indoor allergens
The evidence about a relationship between allergens
and asthma is restricted to inhalant allergens and is
based on either skin tests or serum IgE antibodies.
Thus, there is very little epidemiological data relating
to allergens that are not inhaled. In addition, there is
no  evidence  based  on  T-cell  responses  or  other
isotypes of antibodies. At the time when immunoglo-
bulin (Ig)E was discovered, it was already clear that
the immune response in allergic individuals included
other classes of antibodies, particularly IgG and IgA.12
Subsequently, it became clear that T-cell responses to
purified allergens were common among patients with
asthma and that these T cells were characteristically
Th2 in type.
Recently,  several groups  have suggested that res-
ponses to dust mite and other inhalants are dictated
by events in utero.13,14 However, on critical analysis,
the lymphocyte proliferation data on which that idea
was  based  is  unconvincing.  In  particular,  there  is
very  little  data to  show that cord blood  responses
are  influenced  by  the  exposure  of  the  mother.15
Objective  data  on  immune  responses  to  inhalant
allergens  (i.e.  serology  or  skin  tests  that  can  be
repeated)  is  generally  not  apparent  until  about  2
years of age.16 For allergens derived from dust mites,
there is evidence from Australia, Europe, the United
Kingdom and the USA that the prevalence of sensiti-
zation is directly related to exposure.1 Furthermore,
for dust mites, it is possible to define a ‘community’
threshold for exposure above which sensitization to
mites  will  be  significantly  related  to  asthma.
Although  the  data  for  cockroach  allergens  is  less
extensive, it appears that both sensitization and the
risk of  asthma are also directly related to exposure
to these insects.7,17
By contrast, the evidence related to cat allergens is
not simple. For several years there have been reports
from Scandinavia that children raised in a house with
a cat were less likely to have asthma.18,19The obvious
explanation is that allergic families avoid owning cats.
However,  the  decreased  sensitization  of  children
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Table  1.  High  concentrations  of  cat  allergen are  associated  with  decreased  sensitization*  but  increased  IgG  (and  IgG4)
antibodies to Fel d 1
Exposure to cat allergen Fel d 1 (mg/g)
< 1.6 (n = 75) 1.7–23 (n = 75) 23–3840 (n = 76)
p
Sensitization to cat 12 19 10 ns
IgG antibody to cat 13 24 41 < 0.001
IgG antibody and sensitized 10 6 10 ns
IgG antibody and not sensitized 3 18 31 < 0.001
*Total of 225 middle-school children aged 11 years. Sensitization assessed by skin tests and IgE antibody; data from references 4, 17 and 20.living in a house with a cat is equally present among
children  who  are  atopic  as  judged  by  other  skin
tests.17 Recently,  we have shown that many  of  the
children who are exposed to high concentrations of
cat allergen at home have IgG antibodies to Fel d 1
(Table 1). Furthermore, these IgG antibodies include a
large  proportion  of  IgG4,  an  isotype  that  is  fully
dependent  on  interleukin-4.20 Thus,  this  immune
response to Fel d 1 in children who are not skin-test-
positive to cat, and not symptomatic, we refer to as a
‘modified  Th2  response’.  This  evidence  that  high
exposure  to  an  allergen  can  induce  tolerance  has
many  implications.  These  include:  (i)  that  the
response to high-dose animal  allergen  is  not a Th1
response; (ii) that increasing exposure to cat allergens
cannot explain  the increase in asthma since higher
exposure gives rise to tolerance; and (iii)  that it is
unlikely  that  changes  in  ‘immune  responsiveness’
could have produced the same progressive increase in
asthma in countries where cat allergen is dominant as
in countries where mite is dominant.
Have lifestyle changes altered the
threshold for wheezing?
The  increase  in  asthma  prevalence  over  a  40-year
period looks similar to the increase in type 2 diabetes,
hypertension  or  obesity,  rather  than  any  known
epidemic of infectious disease. In the USA but not in
other countries, this increase has been most severe
among individuals living in poverty and, in particular,
among African Americans  living  in  the  cities.  It  is
therefore essential to examine changes in lifestyle in
the  cities  that  could  be  relevant  to  a  progressive
change  over  40  years.  There  are  three  lines  of
evidence that suggest that lifestyle changes, including
a decline in physical activity, could have lowered the
threshold for wheezing.
1. Bronchial  smooth  muscle  requires  regular  full
extension, or it will start to contract at a shorter
length.21 In keeping with that, normal individuals
will develop broncho hyper-responsiveness (BHR)
if they are prevented from taking deep breaths.22
2. Recent reports that obesity is a risk factor for both
prevalent  and  incident  asthma.23,24 While  it  is
possible that hormonal or other effects related to
obesity influence ‘inflammation’ in the lungs, the
more likely explanation is that obesity is a surro-
gate for decreased activity.
3. The lifestyle changes that characterize poverty in
the  cities  of  the  USA  (and  could  explain  the
difference from poverty elsewhere in the world)
are  poor  diet,  increased  sedentary  time,  and  a
decline in physical activity.25
In  some countries, particularly China and the USA,
the evidence suggests that the increase in asthma has
been  primarily  an  increase  in  wheezing  among
allergic individuals. If this is so, then the increase in
asthma could be seen as a decrease in the threshold
for wheezing. Taking the evidence together, we would
ask has decreased physical activity or prolonged time
spent inactive lowered the threshold for wheezing?
This  effect  could  be  primarily  physiological  (i.e.
related to smooth muscle  function);  the alternative
explanation would be that prolonged exercise plays a
role in  decreasing inflammation or accelerating the
healing of inflammatory foci.
Conclusion
The evidence that children raised in a house with a
cat are less likely to become allergic to cat allergens
has major implications for understanding the role of
immune  responses  to  allergens  in  the  increase  in
asthma.  First,  it  is  clear  that  the  dose  response to
animal  dander  is  different  from  that  to  mite  or
cockroach,  thus  the  effect  of  increasing  exposure
would  not  be  the  same.  Second,  the  finding  that
high exposure to cat allergen can induce a modified
Th2 response strongly argues against the hypothesis
that a shift from Th1 to Th2 could be the basis for
the increase in asthma. Indeed, in our studies, most
non-allergic individuals have no serological evidence
that  they  have  made  an  immune  response.  The
results  imply  that  the  true  explanation  for  the
increase  in  asthma  lies  elsewhere.  Given  the  evi-
dence about  obesity  and  the  physiological  require-
ment of bronchial smooth muscle for full extension,
it becomes increasingly possible that the decline in
physical  activity  has  contributed  to  a  progressive
lowering  of  the  threshold  for  wheezing  among
allergic children.
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Introduction
Atopic dermatitis (AD) is a chronic inflammatory skin
disease clinically and histologically highly similar to
allergic  contact  dermatitis.  Recently,  it  has  been
proposed to subdivide AD into two distinct forms: the
extrinsic form (occurring in the context of sensitiza-
tion toward environmental allergens), and the intrin-
sic  form  (occurring  in  the  absence  of  any  typical
atopical background).1 While the pathophysiology of
the intrinsic form remains almost elusive, tremendous
progress has been made in the understanding of the
extrinsic form. Thus, since IgE plays a major role in
other atopic diseases such as asthma and rhinitis, it is
assumed that, in this extrinsic form, immunoglobulin
E (IgE) also mediated the specificity of the inflamma-
tory conditions in the skin.
Presence of IgE-bearing dendritic cells in
the skin of patients with AD
The emergence of extrinsic AD (i.e. a cell-mediated
inflammation)  in  atopic  patients  (i.e.  individuals
prone  to  have  increased  IgE  production  and  to
develop  IgE-mediated  hypersensitivity  reactions)
remained  puzzling  until  the  mid-1980s,  when  the
presence of IgE molecules on the surface of Langer-
hans cells (LC) from patients presenting AD was first
reported.2,3 A new pathophysiological concept was
proposed in  which  LC  and  inflammatory  dendritic
epidermal cells (IDEC)4 armed with allergen-specific
IgE would trigger an eczematous inflammation.
Molecular structure, regulation and
function of Fc«RI on human dendritic cells
The identity of the relevant IgE-binding structure of
cutaneous dendritic cells (DC) was unclear for some
years, until other workers and myself demonstrated
the  presence  of  the  high-affinity  receptor  for  IgE
(Fc«RI)  on  these cells  as  well  as  on  other antigen
presenting  cells  (APC),  including  monocytes,  and
circulating DC.5–7 It also became clear that Fc«RI on
APC lacks the classical b-chain and thus, in contrast to
effector  cells  of  anaphylaxis  (i.e.  mast  cells  and
basophils that express an a,b,g2 conformation), APC
display an a,g2 conformation that implies profound
functional  consequences.  Moreover,  its  expression
and the function may be highly variable, depending
on  the  microenvironment.8 However,  the  highest
expression is specifically observed in AD skin.9 One
may speculate that Fc«RI ligation on APC putatively
triggers the synthesis and release of mediators that
may initiate a local inflammatory reaction, as has been
demonstrated for mast cells.
Fc«RI/IgE-mediated allergen uptake and subsequent
antigen presentation has been attributed a key event in
the pathogenesis of atopic dermatitis.10 Using this kind
of antigen uptake, APC may, in the presence of antigen-
specific IgE, increase their presenting capacity up to
100-fold.11 This mechanism, also known as ‘antigen
focusing’ or ‘facilitated antigen presentation’, has been
shown  effective  by  different  research  groups  in
different  cell  systems.  The  observation  that  the
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